Correction: Assessment of angle velocity in girls with adolescent idiopathic scoliosis

Correction to Escalada F, Marco E, Duarte E, Muniesa JM, Boza R, Tejero M, Cáceres E. Assessment of angle velocity in girls with adolescent idiopathic scoliosis. Scoliosis 2009; 4:20

Nuevas estrategias terapéuticas en diabetes mellitus tipo 1

El principal determinante del riesgo de complicaciones derivadas de la diabetes mellitus tipo 1 se debe a los altos niveles de glucosa en sangre mantenidos durante largo tiempo. Para conseguir un beneficio terapéutico en pacientes con diabetes mellitus es necesario desarrollar tratamientos que permitan de manera segura, efectiva y estable mantener la normoglucemia. Lamentablemente, el tratamiento de la diabetes mellitus tipo 1 mediante el aporte exógeno de insulina no es capaz de conseguir niveles estables de glucosa en sangre, de manera que con frecuencia se producen casos de severa hipoglucemia o hiperglucemia. Hasta la fecha la única solución para reestablecer de manera permanente la normoglucemia se consigue mediante el trasplante de páncreas o de islotes pancreáticos. Sin embargo, a medida que se incrementa el número de centros especializados en el trasplante de islotes, mayor es la necesidad de islotes para su trasplante. Así pues, el estudio de nuevas fuentes de células productoras de insulina así como de nuevos tratamientos que permitan preservar o incluso aumentar la masa de células beta en los pacientes con diabetes mellitus representa un objetivo de primera necesidad en este campo. En este sentido, en la última década ha habido un avance significativo en el campo de la biología de las células madre. Sin embargo, la identificación de células apropiadas para la generación de nuevas células beta, además del desarrollo de técnicas para la caracterización de estas células, así como de ensayos y modelos animales apropiados para probar su capacidad de diferenciación tanto in vitro como in vivo son de vital importancia para la puesta en marcha de nuevas estrategias terapéuticas basadas en la aplicación de las células madre para el tratamiento de la diabetes mellitus tipo 1

Treatment of type 2 diabetes by patient profile in the clinical practice of endocrinology in Spain: Delphi study results from the think twice program

Introduction: The aim of this Delphi study is to unveil the management of patients with type 2 diabetes (T2D) and different levels of complexity in the clinical practice in Spain. Methods: Based on the common management practices of T2D profiles reported by Spanish endocrinologists, a Delphi questionnaire of 55 statements was developed and responded to by a national panel (n = 101). Results: A consensus was reached for 30 of the 55 statements. Regarding overweight patients inadequately controlled with metformin, treatment with a sodium-glucose transport protein 2 inhibitor (SGLT2-I) is preferred over treatment with a dipeptidyl peptidase-4 inhibitor (DPP4-I). If the patient is already being treated with a DPP4-I, an SGLT2-I is added on to the treatment regimen rather than replacing the DPP4-I. Conversely, if the treatment regimen includes a sulfonylurea, it is usually replaced by other antihyperglycemic agents. Current treatment trends in uncontrolled obese patients include the addition of an SGLT2-I or a glucagon-like peptide-1 receptor agonist (GLP1-RA) to background therapy. When the glycated hemoglobin target is not reached, triple therapy with metformin ? GLP1-RA ? SGLT2-I is initiated. Although SGLT2-Is are the treatment of choice in patients with T2D and heart failure or uncontrolled hypertension, no consensus was reached regarding the preferential use of SGLT2- Is or GLP1-RAs in patients with established cardiovascular disease. Conclusion: Consensus has been reached for a variety of statements regarding the management of several T2D profiles. Achieving a more homogeneous management of complex patients with T2D may require further evidence and a better understanding of the key drivers for treatment choice

Assessment of angle velocity in girls with adolescent idiopathic scoliosis

<p>Abstract</p> <p>Background</p> <p>Although it has been demonstrated that the peak height velocity (PHV) is a predictive factor of progression in adolescent idiopathic scoliosis (AIS), little is known about the usefulness of angle progression in clinical practice. The purpose of this study was to establish a relationship between height and angle velocities, as well as to determine if peak angle velocity (PAV) occurs at the same time than PHV.</p> <p>Methods</p> <p>A retrospective study of a cohort of girls with idiopathic scoliotic curves greater than 10°. Data of 132 girls who participated in a previous retrospective study about growth in AIS were used to calculate height and angle velocities. Relationship between height and angle velocities was estimated by the use of a Linear Mixed Model.</p> <p>Results</p> <p>PHV and PAV take place simultaneously 1 year before menarche in progressive curves managed with a brace in AIS. Changes in angle velocity are influenced by changes in height growth velocity, in such a way that as from 6 months post-menarche, height growth velocity in this group of girls estimates curve progression velocity (β-coefficient -0.88, p = 0.04).</p> <p>Conclusion</p> <p>As from 6 months post-menarche, there is an inverse relationship between height velocity and curve progression in the group of AIS girls with progressive curves managed with a brace. Because height velocity is decreasing from 1 year before menarche, this finding corroborates that at the end of puberty, there is still a risk of progression in this group of girls despite bracing. The assessment of both height and angle velocity might be useful in clinical practice at the time of assessing brace effectiveness and how long bracing has to be indicated.</p

Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis

ABSTRACT Aims: To examine the association of baseline patient characteristics with study outcomes in people with type 2 diabetes receiving insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100), over a 6-month period. Methods: A post hoc patient-level metaanalysis using data from three multicenter, randomized, open-label, parallel-group, phase 3a studies of similar design, in people previously receiving either basal and prandial insulin, basal insulin ? oral antihyperglycemic drugs, or no prior insulin (EDITION 1, 2 and 3, respectively). The endpoints, glycated hemoglobin (HbA1c), hypoglycemia, body weight change, and insulin dose were investigated by subgroups: age (\65 and C 65 years), body mass index (BMI; \ 30 and C 30 kg/m2), age at onset (\40, 40–50, and [ 50 years), and diabetes duration (\ 10 and C 10 years). Results: Reduction in HbA1c was comparable between insulins, regardless of subgroup. The lower risk of C 1 nocturnal (00:00–05:59 h) confirmed (B 3.9 mmol/L [B 70 mg/dL]) or severe hypoglycemic event with Gla-300 versus Gla-100 was also unaffected by participant characteristics. While heterogeneity of treatment effect between diabetes duration subgroups was seen for the risk of C 1 confirmed (B 3.9 mmol/L [B 70 mg/dL]) or severe hypoglycemic event at any time (24 h), treatment effect consistently favored Gla-300; no evidence of heterogeneity was observed for the other subgroups. Annualized rates of confirmed (B 3.9 mmol/L [B 70 mg/dL]) or severe hypoglycemia and body weight change were not influenced by participant characteristics; a similar pattern was observed with insulin dose. Conclusions: Comparable glycemic control was observed with Gla-300 versus Gla-100, with less hypoglycemia, regardless of age, BMI, age at onset or diabetes duration. Funding: Sanofi. Plain Language Summary: Plain language summary available for this article. Keywords: Glycated Hemoglobin A; Hypoglycemia; Insulin Glargine; Type 2 Diabetes PLAIN LANGUAGE SUMMARY Treatments for patients with type 2 diabetes aim to reduce the levels of blood glucose and can include injections with insulin. However, care must be taken to prevent blood glucose levels falling too low (a state called hypoglycemia). Previous studies have shown that insulin glargine 300 units/mL (Gla-300) provides similar reductions in blood glucose levels as insulin glargine 100 units/mL (Gla-100) but is less likely to cause hypoglycemia. However, different patients may respond differently to treatments depending on their individual clinical and biological characteristics. The aim of this study was to evaluate how different profiles of patients with type 2 diabetes responded to Gla-300 and Gla-100 injections. Patients were grouped by different ages, weights, age at diabetes diagnosis, and number of years since diagnosis of diabetes. We found that Gla-300 and Gla-100 reduced glycated hemoglobin (HbA1c; a marker of blood glucose control over the previous 2–3 months) similarly, regardless of how patients were grouped. However, patients treated with Gla-300 were less likely to experience hypoglycemia than those treated with Gla-100, and this association was also true regardless of different patient characteristics. We therefore concluded that Gla-300 is an effective and safe treatment in patients with type 2 diabetes, regardless of their age, weight, age at diabetes diagnosis, and years since diagnosis

Reduced hypoglycemia risk in type 2 diabetes patients switched to/initiating insulin glargine 300 vs 100 U/ml: A european real-world study

Introduction: Randomized controlled trials and real-world data from the USA have shown similar glycemic control with insulin glargine 300 U/ml (Gla-300) and insulin glargine 100 U/ml (Gla-100) and reduced hypoglycemia risk with Gla-300. This real-world study describes the efficacy and safety of Gla-300 and Gla-100 in patients with type 2 diabetes (T2D) in France, Spain, and Germany. Methods: This retrospective chart review analysis used anonymized data for adults with T2D switching basal insulin analog (BIA) therapy to Gla-300 or Gla-100, or insulin-naïve patients initiating Gla-300 or Gla-100. Outcomes included change from baseline to 6-month follow-up in glycated hemoglobin A1c (A1C), total and severe hypoglycemia incidences and events, insulin dose, and reasons for BIA choice. Results: Six hundred sixty-five physicians (33.8% Spain, 31.7% France, 34.4% Germany) provided chart data for patients switching to Gla-300 (n = 679) or Gla-100 (n = 429) or initiating Gla-300 (n = 719) or Gla-100 (n = 711). After adjustment for baseline characteristics, A1C reductions from baseline were similar for patients switching to Gla-300 or Gla-100 (- 0.87% vs. - 0.93%; p = 0.326) while those switched to Gla-300 vs. Gla-100 had a significantly greater mean reduction in hypoglycemic events (- 1.29 vs. - 0.81 events during 6 months; p = 0.012). Mean insulin doses after titration were 0.43 ± 0.36 and 0.40 ± 0.28 U/kg in Gla-300 and Gla-100 switchers, respectively. Factors that significantly influenced BIA choice included a lower risk of hypoglycemia (for Gla-300) and physician familiarity (for Gla-100). Outcomes for insulin-naïve patients were broadly similar to those of switchers. Conclusions: In this real-world European study, patients with T2D who switched therapy to Gla-300 or Gla-100 had improved glycemic control and reduced hypoglycemia at 6 months, with significant hypoglycemia advantages with Gla-300

Influence of drying process and particle size of persimmon fibre on its physicochemical, antioxidant, hydration and emulsifying properties

[EN] Persimmon, given its current surplus production, could be an alternative source for the extraction of certain interesting ingredients for the food industry and human health, such as fibre. Thus, the aim of this study was to analyse the influence of hot air and freeze-drying, as well as the particle size of fibre extracted from persimmon peels or pulp on their physicochemical, antioxidant, hydration and emulsifying properties, compared to commercial fibres (from peach, lemon, orange and apple). The results showed that both freeze-dried persimmon pulp and freeze-dried peel had better hydration properties and oil holding capacity than other fibres analysed, although the swelling capacity was higher for lemon fibre. Freeze-dried persimmon peel fibre showed higher values of emulsion stability than commercial fibres. Finally, the antioxidant activity of the smallest sized persimmon peel fibre obtained by freeze-drying was higher than that for lemon, orange and peach fibre.The authors acknowledge the support of the Universtitat Politecnica de Valencia and certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.Martínez-Las Heras, R.; Landines, E.; Heredia Gutiérrez, AB.; Castelló Gómez, ML.; Andrés Grau, AM. (2017). Influence of drying process and particle size of persimmon fibre on its physicochemical, antioxidant, hydration and emulsifying properties. Journal of Food Science and Technology. 54(9):1-11. doi:10.1007/s13197-017-2728-zS111549Abdul-Hamid A, Luan YS (2000) Functional properties of dietary fibre prepared from defatted rice bran. Food Chem 68:15–19Adams MR, Moss MO (1997) Microbiología de los alimentos. Acribia, ZaragozaAlós C (2014) La superficie cultivada de caqui crece un 20% en 2013 y se quintuplica en una década. http://www.levante-emv.com/comarcas/2014/01/10/superficie-cultivada-caqui-crece-20/1067085.html . Accessed 21 Nov 2015AOAC (1990) Official methods of analysis of the association of official analytical chemists, vol 2, 15th edn. AOAC, Inc. Method 920.152, USA, pp 917AOAC (2000) Official methods of analysis of AOAC international, 17th edn. Gaithersburg, MD, USAArnal L, Del Río MA (2003) Removing astringency by carbon dioxide and nitrogen-enriched atmospheres in persimmon fruit cv. ‘Rojo brillante’. J Food Sci 68:1516–1518Basanta MF, Ponce NMA, Rojas AM, Stortz CA (2012) Effect of extraction time and temperature on the characteristics of loosely bound pectins from Japanese plum. Carbohydr Polym 89:230–235Chau CF, Wang YT, Wen YL (2007) Different micronization methods significantly improve the functionality of carrot insoluble fibre. Food Chem 100:1402–1408Chen XN, Fan JF, Yue X, Wu XR, Li LT (2008) Radical scavenging activity and phenolic compounds in persimmon (Diospyros kaki L. cv. Mopan). J Food Sci 73:24–28de Escalada Pla MF, González P, Sette P, Portillo F, Rojas AM, Gerschenson LN (2012) Effect of processing on physico-chemical characteristics of dietary fibre concentrates obtained from peach (Prunus persica L.) peel and pulp. Food Res Int 49:184–192de Moraes Crizel T, Jablonski A, de Oliveira Rios A, Rech R, Flôres SH (2013) Dietary fiber from orange byproducts as a potential fat replacer. LWT-Food Sci Technol 53:9–14Femenia A, Lefebvre AC, Thebaudin JY, Robertson JA, Bourgeois CM (1997) Physical and sensory properties of model foods supplemented with cauliflower fibre. J Food Sci 62:635–639Femenia A, Selvendran RR, Ring SG, Robertson JA (1999) Effects of heat treatment and dehydration on properties of cauliflower fiber. J Agric Food Chem 47:728–732Figuerola F, Hurtado ML, Estevez AM, Asenjo F (2005) Fiber concentrate from apple pomace and citrus peel as potential fiber sources for food enrichment. Food Chem 91(3):395–401Garau MC, Simal S, Rosselló C, Femenia A (2007) Effect of air-drying temperature on physico-chemical properties of dietary fibre and antioxidant capacity of orange (Citrus aurantium v. Canoneta) by-products. Food Chem 104:1014–1024George AP, Redpath S (2008) Health and medicinal benefits of persimmon fruit: a review. Adv Hort Sci 22:244–249Gorinstein S, Bartnikowska E, Kulasek G, Zemser M, Trakhtenberg S (1998) Dietary persimmon improves lipid metabolism in rats fed diets containing cholesterol. J Nutr 128:2023–2027Gorinstein S, Kulasek G, Bartnikowska E, Leontowicz M, Zemser M, Morawiec M (2000) The effects of diets, supplemented with either whole persimmon or phenol-free persimmon, on rats fed cholesterol. Food Chem 3:303–308Hernándiz A (1999) El cultivo de kaki en la comunidad valenciana. Cuadernos de tecnología agraria serie fructicultura No. 3 Generalitat Valenciana Conselleria de Agricultura, Pesca y AlimentaciónINE (2014) Instituto Nacional de Estadística, Spanish Statistical Office. http://www.ine.es/dyngs/INEbase/es/categoria.htm?c=Estadistica_P&cid=1254735727106 . Accessed 15 Dec 2014Kethireddipalli P, Hung YC, Phillips RD, McWatters KH (2002) Evaluating the role of cell wall material and soluble protein in the functionality of cowpea (Vigna unguiculata) pastes. J Food Sci 67:53–59López G, Ros G, Rincón F, Periago MJ, Martínez MC, Ortuno J (1996) Relationship between physical and hydration properties of soluble and insoluble fiber of artichoke. J Agric Food Chem 44:2773–2778Ministry of Agriculture of Spain (2013). http://www.magrama.gob.es/es/ . Accessed 12 Dec 2013Perez-Jimenez J, Diaz-Rubio ME, Mesias M, Morales FJ, Saura-Calixto F (2014) Evidence for the formation of maillardized insoluble dietary fiber in bread: a specific kind of dietary fiber in thermally processed food. Food Res Int 55:391–396Raghavendra SN, Rastogi NK, Raghavarao KSMS, Tharanathan RN (2004) Dietary fiber from coconut residue: effects of different treatments and particle size on the hydration properties. Eur Food Res Technol 218:563–567Rajendran P, Nandakumar N, Rengarajan T, Palaniswami R, Gnanadhas EN, Lakshminarasaiah U, Nishigaki I (2014) Antioxidants and human diseases. Clin Chim Acta 436:332–347Robertson JA, Monredon FD, Dysseler P, Guillon F, Amadó R (2000) Hydration properties of dietary fiber and resistant starch: a European collaborative study. LWT-Food Sci Technol 33:72–79Sakanaka S, Tachibana Y, Okada Y (2005) Preparation and antioxidant properties of extracts of Japanese persimmon leaf tea (kakinoha-cha). Food Chem 89:569–575Shahidi F, Liyana-Pathirana CM, Wall DS (2006) Antioxidant activity of white and black sesame seeds and their hull fractions. Food Chem 99:478–483Singh U (2001) Functional properties of grain legume flours. J Food Sci Technol 38:191–199Storey M, Anderson P (2014) Income and race/ethnicity influence dietary fiber intake and vegetable consumption. Nutr Res 34:844–850Thebaudin JY, Lefebvre AC, Harrington M, Bourgeois CM (1997) Dietary fibres: nutritional and technological interest. Trends Food Sci Technol 8:41–48Vetter S, Kunzek H (2003) The influence of suspension solution conditions on the rehydration of apple cell wall material. Eur Food Res Technol 216:39–45Yasumatsu K, Sawada K, Maritaka S, Mikasi M, Toda J, Wada T, Ishi K (1972) Whipping and emulsifying properties of soybean products. Agric Biol Chem Tokyo 36:719–727Zha XQ, Wang JH, Yang XF, Liang H, Zhao LL, Bao SH, Zhou BB (2009) Antioxidant properties of polysaccharide fractions with different molecular mass extracted with hot-water from rice bran. Carbohydr Polym 78:570–57

Farmacogenómica en el cáncer colorrectal

La investigación en el proyecto genoma humano va a favorecer en los próximos años el desarrollo farmacoterapias más personalizadas. La Farmacogenómica es una nueva disciplina que se ha desarrollado en los últimos años y cuyos objetivos se dirigen a conocer aquellos mecanismos que permitan explicar cómo la base genética de cada individuo afecta a la respuesta obtenida a las drogas. La posibilidad de predecir qué terapias son más efectivas para un determinado paciente va a constituir una poderosa herramienta médica, particularmente en el ámbito de la oncología. Es probable que estas predic- ciones deriven de una mejor comprensión de la enfermedad tanto a nivel celular como molecular. Por lo que respecta al cáncer colorrectal, los avances en el conocimiento de la etiología de la enfermedad a nivel molecular no se han asociado con una mejora en el tratamiento del paciente. La eficacia clínica y la toxicidad de las drogas más utilizadas en el tratamiento del cáncer colorrectal de cada paciente son por el momento impredecibles. Entre otras muchas variables, se han descrito determinados polimorfismos en genes implicados en el metabolismo de estas drogas que determinan la variabilidad interindividual tanto en la eficacia terapeútica como en la toxicidad. La investigación de las características moleculares del cáncer colorrectal y el desarrollo de nuevas terapias dirigidas a dianas específicas van a permitir en el futuro predecir la respuesta de la neoplasia y, por tanto, modificar la opción terapeútica buscando aquella que mejor se ajuste al perfil biológico.Advances in human genome research will make it possible to personalize pharmacotherapy. Pharmacogenomics has been defined as the study of mechanisms that explain how an individual's genetic inheritance affects the response to drugs. The ability to predict which therapies are most likely to be effective for certain patients would constitute a powerful medical tool, particularly in oncology. Such predictions would be likely to arise from an understanding of the disease on the cellular and molecular level. For colorectal cancer, our increased knowledge of the molecular etiology of the disease has not yet been paralleled by an improvement in patient care. Clinical efficacy and also toxicity of a given chemotherapy are still largely unpredictable for the individual patient. Amongst other variables, genetic polymorphisms determine the interindividual heterogeneity in both toxicity and therapeutic efficacy. Due to the better molecular characterization of colorectal cancer and the development of new target-directed therapies, it should be possible to predict which therapeutic interventions will have a high likelihood of success for an individual patient